En esta página
01LSTA precio
02Instantánea
03Gráfico
04Divisiones de acciones
05Acerca de
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
18Activistas y propietarios del %+ 5
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
23Noticias
26Mis Métricas
LSTA Lisata Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 6, 2026
$1,47
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$0,99mínimo 52 semanas
$5,07máximo 52 semanas
Capitalización Bursátil (MRQ)
$13M
P/E (TTM)
-0.9
BPA (TTM)
$-1.64
Ingresos (TTM)
$100.0K
tus insignias
Rango 52S
$1–$5
Calificación del Analista
BUY
Precio Objetivo
$4
P/E
-0.9
ROE
-99.9%
Margen de Beneficio Neto
-14621.0%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
LSTA Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$1.47
Capitalización Bursátil (MRQ)
$13M
P/E (TTM)
-0.9
BPA (TTM)
$-1.64
Ingresos (TTM)
$100.0K
ROE (TTM)
-99.9%
Rango 52S
$1–$5
LSTA Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Divisiones de acciones
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 15 de septiembre de 2022 | 1-for-15 | Inversa |
| 28 de julio de 2016 | 1-for-10 | Inversa |
| 16 de julio de 2013 | 1-for-10 | Inversa |
| 9 de agosto de 2007 | 1-for-10 | Inversa |
| 31 de agosto de 2006 | 1-for-10 | Inversa |
Acerca de Lisata Therapeutics, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide (also known as iRGD and CEND-1), orphan drug status in pancreatic cancer, followed by a Fast track (FDA) status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.
== References ==
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
sectorHealthcare
industriaBiotechnology
empleados21
paísUS
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$170.0K2016-12-31 → 2025-12-31
BPA$-1.912016-12-31 → 2025-12-31
Flujo de caja libre·2016-12-31 → 2023-12-31
Margen neto-14621.0%2016-12-31 → 2024-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | LSTA | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -0.9promedio 5A ≈-1.0 | ≈-1.0 | · | · | |
| P/S (TTM) | 134.0 | · | · | · | |
| P/C (MRQ) | 1.6promedio 5A ≈0.5 | ≈0.5 | · | · | |
| Precio / FCF (TTM) | -1.1 | · | · | · | |
| Precio / Flujo de Caja (TTM) | -1.1promedio 5A ≈-1.1 | ≈-1.1 | · | · | |
| Precio / Valor Contable Tangible (MRQ) | 1.7promedio 5A ≈2.2 | ≈2.2 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | LSTA | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | -16428.0% | · | · | · | |
| Margen antes de impuestos (TTM) | -15008.0% | · | · | · | |
| Margen de Beneficio Neto (TTM) | -14621.0% | · | · | · | |
| ROA (TTM) | -80.8%promedio 5A ≈-47.0% | ≈-47.0% | -106.4% | De primer nivel | |
| ROE (TTM) | -99.9%promedio 5A ≈-52.0% | ≈-52.0% | -135.0% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | LSTA | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 3.7promedio 5A ≈8.5 | ≈8.5 | 4.3 | Baja liquidez |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | LSTA | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | -83.0% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | LSTA | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue / Employee (Ingresos / Empleado) | ≈$8.1K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
14.0%
Próximo informe
Nov 04, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de septiembre de 2025 | $-0.49 | $-0.55 | 10.2% | |
| 30 de junio de 2025 | $-0.54 | $-0.66 | 18.6% | |
| 31 de marzo de 2025 | $-0.55 | $-0.54 | -1.7% | |
| 31 de diciembre de 2024 | $-0.55 | $-0.78 | 29.1% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.0K | $1M | $0 | $0 | · | · | · | · | · | $35M | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $31M | |
| R&D Expense | · | · | · | · | $18M | $9M | $11M | $8M | $16M | $17M | |
| SG&A Expense | $10M | $12M | $13M | $14M | $11M | $10M | $9M | $9M | $12M | $13M | |
| Operating Expenses | $18M | $23M | $26M | $58M | $29M | $19M | $20M | $17M | $28M | $30M | |
| Operating Income | $-18M | $-22M | $-26M | $-58M | $-29M | $-19M | $-20M | $-17M | $-28M | $-30M | |
| Interest Expense | · | · | · | · | · | · | $0 | $5.0K | $378.0K | $2M | |
| Other Non-op | $-145.0K | $-257.0K | $-186.0K | $-155.0K | $-75.0K | $0 | $740.0K | $824.0K | $273.0K | $23.9K | |
| Pretax Income | $-18M | $-21M | $-23M | $-57M | $-29M | $-19M | $-19M | $-16M | $-28M | $-31M | |
| Income Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-12M | $0 | |
| Net Income | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| EPS (Basic) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | $-1.67 | $2.56 | $-4.99 | |
| EPS (Diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 | |
| Shares (Basic) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| Shares (Diluted) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| EBITDA | · | $-22M | $-26M | $-58M | · | $-19M | $-20M | $-17M | $-27M | $-30M |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $16M | $23M | $32M | $25M | $17M | $14M | $10M | $29M | $7M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $26M | $0 | |
| Receivables | $0 | $900.0K | $0 | · | · | · | · | · | $234.5K | $138.8K | |
| Prepaid Expense | $2M | $2M | $3M | $3M | $1M | $758.0K | $815.0K | $1M | $1M | $2M | |
| Current Assets | $18M | $35M | $54M | $72M | $96M | $35M | $26M | $44M | $61M | $25M | |
| PP&E (Net) | $18.0K | $72.0K | $175.0K | $296.0K | $62.0K | $57.0K | $100.0K | $165.0K | $257.0K | $705.4K | |
| PP&E (Gross) | $494.0K | $661.0K | $661.0K | $713.0K | $430.0K | $370.0K | $349.0K | $349.0K | $1M | $2M | |
| Accum. Depreciation | $476.0K | $589.0K | $486.0K | $417.0K | $368.0K | $313.0K | $249.0K | $184.0K | $832.0K | $1M | |
| Goodwill | · | · | · | · | · | · | · | · | · | $7M | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $0 | · | · | · | · | $2M | |
| Other Non-current Assets | $23.0K | $160.0K | $332.0K | $528.0K | $764.0K | $614.0K | $1M | $309.0K | $2M | $2M | |
| Total Assets | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Accounts Payable | $1M | $1M | $2M | $3M | $2M | $1M | $1M | $762.0K | $1M | $2M | |
| Accrued Liabilities | $2M | $4M | $4M | $4M | $3M | $2M | $4M | $5M | $8M | $3M | |
| Short-term Debt | · | · | · | · | · | · | · | $0 | $159.0K | $563.8K | |
| Current Liabilities | $3M | $6M | $7M | $6M | $5M | $4M | $6M | $6M | $9M | $21M | |
| Capital Leases | $0 | $0 | $137.0K | $305.0K | $485.0K | $254.0K | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $1M | |
| Other Non-current Liabilities | $72.0K | $72.0K | $210.0K | $327.0K | $485.0K | $254.0K | $624.0K | $2M | $4M | $389.9K | |
| Total Liabilities | $3M | $6M | $7M | $7M | $5M | $4M | $7M | $7M | $13M | $30M | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $6M | |
| Total Debt | · | · | · | · | · | · | · | $0 | $159.2K | $6M | |
| Common Stock | $9.0K | $8.0K | $8.0K | $8.0K | $4.0K | $19.0K | $11.0K | $10.0K | $9.0K | $8.2K | |
| Paid-in Capital | $580M | $578M | $577M | $575M | $546M | $459M | $439M | $436M | $433M | $410M | |
| Retained Earnings | $-565M | $-548M | $-528M | $-507M | $-453M | $-426M | $-417M | $-398M | $-382M | $-405M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $707.6K | |
| AOCI | $-37.0K | $-81.0K | $-42.0K | $-29.0K | $-70.0K | $-13.0K | $2.0K | $-32.0K | $-28.0K | $0 | |
| Stockholders' Equity | $15M | $30M | $48M | $67M | $92M | $32M | $21M | $38M | $51M | $5M | |
| Liabilities + Equity | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Shares Outstanding | 8,833,875 | 8,410,000 | 8,151,000 | 7,867,000 | 3,986,000 | 1,292,000 | 10,517,609 | 9,865,735 | 9,483,911 | 8,205,790 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146.0K | $174.0K | $189.0K | $69.0K | $55.0K | $100.0K | $100.0K | $200.0K | $400.0K | $500.0K | |
| Stock-based Comp | $1M | $2M | $2M | · | · | · | · | · | · | · | |
| Deferred Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-576.0K | $0 | |
| Amort. of Intangibles | $65.0K | $71.0K | $71.0K | $21.0K | · | · | · | · | · | $570.0K | |
| Other Non-cash | · | · | $3M | $35M | · | $10M | $379.0K | $-4M | $-44M | $8M | |
| Operating Cash Flow | $-16M | $-19M | $-20M | $-21M | $-22M | $-9M | $-19M | $-20M | $-21M | $-24M | |
| CapEx | $28.0K | $0 | $0 | $285.0K | $60.0K | $20.0K | $0 | $134.0K | $135.0K | $1M | |
| Investing Cash Flow | $15M | $13M | $10M | $29M | $-55M | $-7M | $21M | $-5M | $41M | $-3M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | $-6M | $-9M | |
| Stock Issued | $844.0K | $68.0K | $321.0K | $43.0K | $86M | $19M | · | · | · | · | |
| Net Stock Activity | · | $68.0K | $321.0K | $43.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $599.0K | $-206.0K | $385.0K | $-224.0K | $85M | $19M | $1M | $824.0K | $-932.0K | $21M | |
| Net Change in Cash | $-253.0K | $-6M | $-10M | $8M | $8M | $2M | $4M | $-24M | · | $-6M | |
| Taxes Paid | $6.0K | $6.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | $-20M | $-21M | · | $-9M | $-19M | $-20M | $-21M | $-27M | |
| Levered FCF | · | · | · | · | · | · | $-19M | $-20M | $-21M | $-28M |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -2240.9% | · | · | · | · | · | · | · | -88.8% | |
| Net Margin | · | -1998.5% | · | · | · | · | · | · | · | -94.4% | |
| Pretax Margin | · | -2078.3% | · | · | · | · | · | · | · | -94.0% | |
| EBITDA Margin | · | -2240.9% | · | · | · | · | · | · | · | -83.7% | |
| ROA | · | -44.6% | -32.6% | -63.8% | · | -25.8% | -54.0% | -29.9% | 39.3% | -57.9% | |
| ROE | · | -51.4% | -36.3% | -68.3% | · | -30.6% | -66.1% | -36.6% | 83.0% | -232.9% | |
| ROIC | · | -72.9% | -48.0% | -82.7% | · | -25.2% | -96.5% | -45.0% | -31.8% | -276.4% |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 6.2 | 8.2 | 11.3 | · | 10.1 | 4.3 | 7.8 | 6.6 | 1.3 | |
| Quick Ratio | · | 3.0 | 3.4 | 5.0 | · | 4.7 | 2.3 | 1.8 | 5.9 | 0.9 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.0 | 0.0 | 1.3 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -3397.4 | -73.0 | -16.9 |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | · | · | · | · | · | · | 0.6 | |
| Receivables Turnover | · | 2.2 | · | · | · | · | · | · | · | 12.9 |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $3.52 | $5.91 | $8.46 | · | $1.68 | $1.98 | $3.82 | $5.33 | $0.60 | |
| Revenue / Share | · | $0.12 | $0.00 | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-2.32 | $-2.48 | $-4.09 | · | · | · | $-2.06 | $-2.33 | · | |
| Cash / Share | · | $1.93 | $2.77 | $4.09 | · | $0.85 | $1.33 | $1.04 | $3.08 | $1.79 | |
| EPS (TTM) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -83.0% | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $170.0K | $1M | $0 | $0 | $33M | $33M | $33M | $33M | $33M | $35M | |
| Net Income TTM | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| Market Cap | · | $25M | $22M | $20M | · | $416M | $396M | $527M | $499M | $348M | |
| Enterprise Value | · | · | · | · | · | · | · | $517M | $444M | $340M | |
| P/E | -1.0 | -1.2 | -1.1 | -0.2 | -1.7 | -40.5 | · | · | 20.6 | -8.5 | |
| P/S | · | 25.1 | · | · | · | 12.6 | 12.0 | 15.9 | 15.1 | 9.9 | |
| P/B | · | 0.8 | 0.5 | 0.3 | · | 12.8 | 19.0 | 14.0 | 9.9 | 71.3 | |
| P / Tangible Book | 1.1 | 0.9 | 0.5 | 0.3 | 8.2 | 12.8 | · | · | · | · | |
| P / Cash Flow | · | -1.3 | -1.1 | -0.9 | · | -47.1 | -21.0 | -26.4 | -23.9 | -14.7 | |
| P / FCF | · | · | -1.1 | -0.9 | · | -47.0 | -21.0 | -26.2 | -23.8 | -13.1 | |
| EV / EBITDA | · | · | · | · | · | · | · | -30.8 | -16.3 | -11.5 | |
| EV / FCF | · | · | · | · | · | · | · | -25.7 | -21.2 | -12.8 | |
| EV / Revenue | · | · | · | · | · | · | · | 15.6 | 13.5 | 9.6 | |
| Earnings Yield | -102.7% | -80.5% | -94.5% | -413.8% | -59.1% | -2.5% | · | · | 4.9% | -11.8% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $100.0K | $0 | $70.0K | $0 | $1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $3M | $4M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $4M | |
| Operating Expenses | $4M | $5M | $3M | $4M | $5M | $6M | $6M | $5M | $6M | $7M | $6M | $6M | $7M | $7M | $7M | $38M | |
| Operating Income | $-4M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-6M | $-7M | $-6M | $-6M | $-7M | $-7M | $-7M | $-38M | |
| Other Non-op | $984.0K | $-54.0K | $-15.0K | $-18.0K | $-7.0K | $-105.0K | $-11.0K | $-45.0K | $-14.0K | $-187.0K | $-12.0K | $-11.0K | $-150.0K | $-13.0K | $-7.0K | $0 | |
| Pretax Income | $-3M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-5M | $-6M | $-5M | $-5M | $-6M | $-6M | $-6M | $-37M | |
| Income Tax | $0 | $-387.0K | $0 | $0 | $0 | $-962.0K | $0 | $0 | $0 | $-798.0K | $0 | $0 | $-2M | $0 | $0 | $0 | |
| Net Income | $-3M | $-4M | $-3M | $-4M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-4M | $-6M | $-6M | $-37M | |
| EPS (Basic) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| EPS (Diluted) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| Shares (Basic) | 9,106,000 | 9,006,000 | · | 8,738,000 | 8,605,000 | 8,602,000 | · | 8,321,000 | 8,308,000 | 8,294,000 | · | 8,141,000 | 8,021,000 | 7,987,000 | · | 4,747,000 | |
| Shares (Diluted) | 9,106,000 | 9,006,000 | · | 8,738,000 | 8,605,000 | 8,602,000 | · | 8,321,000 | 8,308,000 | 8,294,000 | · | 8,141,000 | 8,021,000 | 7,987,000 | · | 4,747,000 | |
| EBITDA | $-4M | $-5M | · | $-4M | $-5M | $-6M | · | $-5M | $-6M | $-7M | · | $-6M | $-7M | $-7M | · | $-38M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $13M | $16M | $19M | $17M | $20M | $16M | $20M | $28M | $22M | $23M | $32M | $24M | $28M | $32M | $31M | |
| Receivables | · | · | $0 | · | · | · | $900.0K | · | · | · | $0 | · | · | · | · | · | |
| Prepaid Expense | $570.0K | $960.0K | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $3M | $3M | $4M | $4M | $3M | $2M | |
| Current Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $42M | $48M | $54M | $57M | $61M | $65M | $72M | $77M | |
| PP&E (Net) | $14.0K | $16.0K | $18.0K | $22.0K | $48.0K | $74.0K | $72.0K | $96.0K | $119.0K | $146.0K | $175.0K | $204.0K | $233.0K | $262.0K | $296.0K | $299.0K | |
| PP&E (Gross) | $494.0K | $494.0K | $494.0K | $494.0K | $566.0K | $689.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $713.0K | · | |
| Accum. Depreciation | $480.0K | $478.0K | $476.0K | $472.0K | $518.0K | $615.0K | $589.0K | $565.0K | $542.0K | $515.0K | $486.0K | $457.0K | $428.0K | $399.0K | $417.0K | · | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $352.0K | |
| Other Non-current Assets | $0 | $23.0K | $23.0K | $23.0K | $70.0K | $116.0K | $160.0K | $201.0K | $246.0K | $290.0K | $332.0K | $371.0K | $410.0K | $449.0K | $528.0K | $588.0K | |
| Total Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Accounts Payable | $836.0K | $510.0K | $1M | $619.0K | $782.0K | $602.0K | $1M | $556.0K | $728.0K | $1M | $2M | $1M | $775.0K | $1M | $3M | $974.0K | |
| Accrued Liabilities | $2M | $3M | $2M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | |
| Current Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $4M | $5M | $7M | $5M | $4M | $5M | $6M | $6M | |
| Capital Leases | · | · | $0 | · | · | · | $0 | $0 | $47.0K | $92.0K | $137.0K | $181.0K | $223.0K | $265.0K | $305.0K | $345.0K | |
| Other Non-current Liabilities | $50.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $119.0K | $164.0K | $210.0K | $253.0K | $295.0K | $337.0K | $327.0K | $367.0K | |
| Total Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $5M | $5M | $7M | $5M | $5M | $6M | $7M | $7M | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | |
| Paid-in Capital | $581M | $581M | $580M | $580M | $579M | $579M | $578M | $578M | $578M | $577M | $577M | $576M | $576M | $575M | $575M | $574M | |
| Retained Earnings | $-572M | $-569M | $-565M | $-562M | $-557M | $-553M | $-548M | $-543M | $-539M | $-533M | $-528M | $-523M | $-517M | $-513M | $-507M | $-501M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | |
| AOCI | $-17.0K | $-21.0K | $-37.0K | $-42.0K | $-50.0K | $-78.0K | $-81.0K | $-32.0K | $-77.0K | $-104.0K | $-42.0K | $-100.0K | $-50.0K | $-52.0K | $-29.0K | $-90.0K | |
| Stockholders' Equity | $8M | $11M | $15M | $17M | $21M | $25M | $30M | $34M | $38M | $43M | $48M | $53M | $58M | $61M | $67M | $72M | |
| Liabilities + Equity | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Shares Outstanding | 9,119,004 | 9,107,291 | 8,833,875 | 8,755,948 | 8,626,464 | 8,620,162 | 8,408,844 | 8,319,600 | 8,321,061 | 8,307,433 | 8,149,897 | 8,139,449 | 8,132,357 | 7,998,342 | 7,866,061 | 7,862,602 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.0K | $2.0K | $15.0K | $44.0K | $44.0K | $43.0K | $41.0K | $42.0K | $45.0K | $46.0K | $47.0K | $47.0K | $47.0K | $48.0K | · | $8.0K | |
| Stock-based Comp | $214.0K | $364.0K | · | · | $239.0K | $530.0K | · | · | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $0 | $0 | $12.0K | $18.0K | $18.0K | $17.0K | $18.0K | $18.0K | $18.0K | $17.0K | $17.0K | $18.0K | $18.0K | $18.0K | $18.0K | · | |
| Operating Cash Flow | $-3M | $-3M | $-3M | $-3M | $-4M | $-5M | $-5M | $-3M | $-5M | $-7M | $-4M | $-4M | $-4M | $-8M | $-6M | $-4M | |
| CapEx | $0 | $0 | $0 | $0 | $0 | $28.0K | $0 | $0 | $0 | $0 | · | $0 | · | · | $26.0K | $24.0K | |
| Investing Cash Flow | $0 | $0 | $0 | $5M | $505.0K | $9M | $1M | $-6M | $12M | $6M | $-6M | $12M | $-725.0K | $4M | $7M | $2M | |
| Stock Issued | $29.0K | $0 | $205.0K | $353.0K | $74.0K | $212.0K | $36.0K | $0 | $32.0K | $0 | $24.0K | $0 | · | · | $14.0K | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $212.0K | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $29.0K | $181.0K | $205.0K | $353.0K | $64.0K | $-23.0K | $-96.0K | $0 | $32.0K | $-142.0K | $24.0K | $-6.0K | $452.0K | $-85.0K | $14.0K | $-99.0K | |
| Net Change in Cash | $-3M | $-3M | $-3M | $2M | $-3M | $4M | $-3M | $-9M | $6M | $-788.0K | $-10M | $9M | $-4M | $-4M | $676.0K | $-2M | |
| Free Cash Flow | · | $-3M | · | · | · | $-5M | · | · | · | · | · | · | · | · | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -16.2% | -20.9% | · | -14.2% | -13.8% | -12.2% | · | -10.2% | -9.6% | -9.4% | · | -7.7% | -5.4% | -7.8% | · | -41.3% | |
| ROE | -20.0% | -24.8% | · | -16.6% | -15.7% | -13.8% | · | -11.4% | -10.5% | -10.4% | · | -8.4% | -5.7% | -8.3% | · | -43.8% | |
| ROIC | -48.4% | -41.6% | · | -25.4% | -23.2% | -19.2% | · | -15.8% | -14.4% | -13.4% | · | -11.3% | -7.5% | -11.2% | · | -52.4% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | · | 4.7 | 5.8 | 7.5 | · | 8.0 | 9.4 | 8.9 | · | 11.2 | 14.1 | 12.4 | · | 12.1 | |
| Quick Ratio | 3.5 | 3.9 | · | 4.2 | 3.9 | 5.3 | · | 4.2 | 6.3 | 4.1 | · | 6.3 | 5.4 | 5.3 | · | 4.9 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.90 | $1.20 | · | $1.98 | $2.44 | $2.94 | · | $4.05 | $4.60 | $5.18 | · | $6.51 | $7.13 | $7.62 | · | $9.16 | |
| Revenue / Share | $0.00 | $0.00 | · | $0.00 | $0.01 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.34 | · | · | · | $-0.63 | · | · | · | $-0.85 | · | · | · | $-1.03 | · | · | |
| Cash / Share | $1.15 | $1.43 | · | $2.17 | $1.95 | $2.35 | · | $2.34 | $3.40 | $2.62 | · | $3.98 | $2.91 | $3.52 | · | $4.00 | |
| EPS (TTM) | $-1.64 | $-1.86 | · | $-2.13 | $-2.23 | $-2.30 | · | $-2.51 | $-2.57 | $-2.46 | · | $-1.82 | $-9.05 | $-10.19 | · | $-15.99 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $100.0K | $170.0K | · | $1M | $1M | $1M | · | $0 | $0 | $0 | · | $0 | $0 | · | · | · | |
| Net Income TTM | $-15M | $-16M | · | $-18M | $-19M | $-19M | · | $-21M | $-21M | $-20M | · | $-21M | $-54M | $-56M | · | $-55M | |
| Market Cap | $31M | $46M | · | $23M | $25M | $20M | · | $25M | $29M | $26M | · | $17M | $30M | $26M | · | $36M | |
| P/E | -2.1 | -2.7 | · | -1.2 | -1.3 | -1.0 | · | -1.2 | -1.4 | -1.3 | · | -1.2 | -0.4 | -0.3 | · | -0.3 | |
| P/S | 310.0 | 268.4 | · | 21.4 | 23.4 | 20.3 | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.8 | 4.2 | · | 1.3 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Tangible Book | 4.0 | 4.3 | · | 1.4 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Cash Flow | · | -14.8 | · | · | · | -3.8 | · | · | · | -3.7 | · | · | · | -3.2 | · | · | |
| Earnings Yield | -48.2% | -37.1% | · | -81.3% | -76.9% | -97.9% | · | -83.7% | -74.1% | -78.8% | · | -85.0% | -244.6% | -313.5% | · | -345.4% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $170.0K | $1M | $0 | $0 | · |
| Margen Operativo % | · | -2240.9% | · | · | · |
| Beneficio neto | $-17M | $-20M | $-21M | $-54M | $-27M |
| EPS Diluido | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | · | 6.2 | 8.2 | 11.3 | · |
| Ratio Rápido | · | 3.0 | 3.4 | 5.0 | · |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | · | · | $-20M | $-21M | · |
Propietarios institucionales (13F) 34 declarantes · $4.1M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
34
Valor en tenencia
$4.1M
Nuevas posiciones
3
Posiciones cerradas
5
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 3 (-11 vs trimestre anterior) | 5 (+1 vs trimestre anterior) | 9 (+4 vs trimestre anterior) | 5 (+2 vs trimestre anterior) | +32K |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $948 046 | 278 837 | 23,31% | Acciones |
| VANGUARD GROUP INC | $503 891 | 270 909 | 12,39% | Acciones |
| Yakira Capital Management, Inc. | $471 107 | 138 561 | 11,58% | Acciones |
| CSS LLC/IL | $375 435 | 110 422 | 9,23% | Acciones |
| DELTEC ASSET MANAGEMENT LLC | $282 870 | 83 197 | 6,96% | Acciones |
| Rangeley Capital, LLC | $275 400 | 81 000 | 6,77% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $246 999 | 72 632 | 6,07% | Acciones |
| BlackRock, Inc. | $186 514 | 54 857 | 4,59% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $166 478 | 48 964 | 4,09% | Acciones |
| GTS SECURITIES LLC | $102 680 | 30 200 | 2,52% | Acciones |
| STATE STREET CORP | $86 183 | 25 348 | 2,12% | Acciones |
| JANE STREET GROUP, LLC | $63 720 | 18 741 | 1,57% | Acciones |
| CITADEL ADVISORS LLC | $52 839 | 15 541 | 1,30% | Acciones |
| NORTHERN TRUST CORP | $52 816 | 15 534 | 1,30% | Acciones |
| JBF Capital, Inc. | $48 780 | 14 347 | 1,20% | Acciones |
| Cerity Partners LLC | $41 422 | 12 183 | 1,02% | Acciones |
| BANK OF AMERICA CORP /DE/ | $35 200 | 10 353 | 0,87% | Acciones |
| HighTower Advisors, LLC | $34 143 | 10 042 | 0,84% | Acciones |
| SOL Capital Management CO | $29 342 | 12 175 | 0,72% | Acciones |
| COOK WEALTH MANAGEMENT GROUP LLC | $29 342 | 12 175 | 0,72% | Acciones |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $16 800 | 5 000 | 0,41% | Acciones |
| Founders Capital Management | $5 668 | 1 667 | 0,14% | Acciones |
| Vanguard Global Advisers, LLC | $3 512 | 1 033 | 0,09% | Acciones |
| Connective Capital Management, LLC | $3 454 | 1 016 | 0,08% | Acciones |
| Tower Research Capital LLC (TRC) | $2 468 | 726 | 0,06% | Acciones |
| OSAIC HOLDINGS, INC. | $680 | 200 | 0,02% | Acciones |
| Caitong International Asset Management Co., Ltd | $306 | 90 | 0,01% | Acciones |
| MORGAN STANLEY | $255 | 75 | 0,01% | Acciones |
| BARCLAYS PLC | $238 | 70 | 0,01% | Acciones |
| Virtu Financial LLC | $200 | 58 782 | 0,00% | Acciones |
| SBI Securities Co., Ltd. | $24 | 7 | 0,00% | Acciones |
| Cheviot Value Management, LLC | $10 | 3 | 0,00% | Acciones |
| Fortitude Family Office, LLC | $3 | 1 | 0,00% | Acciones |
| ROYAL BANK OF CANADA | $0 | 52 | 0,00% | Acciones |
Activistas y propietarios del %+ 5 20 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| RimAsia Capital Partners, L.P., RimAsia Capital Partners GP, L.P., RimAsia Capital Partners GP, Ltd., Eric H.C. Wei ×8 presentaciones | 20 de mayo de 2010 | · | Presentación inicial | Inversión pasiva | SEC |
| Robin L. Smith | 10 de septiembre de 2009 | · | Presentación inicial | Inversión pasiva | SEC |
| Catherine M. Vaczy | 10 de septiembre de 2009 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 16 de noviembre de 2007 | · | Presentación inicial | · | SEC |
| Persona informante no revelada | 30 de octubre de 2007 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 20 de febrero de 2007 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 5 de enero de 2007 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 15 de diciembre de 2006 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 29 de junio de 2006 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada, Persona informante no revelada | 29 de junio de 2006 | · | Presentación inicial | Inversión pasiva | SEC |
| Mark Weinreb | 29 de junio de 2006 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 28 de junio de 2006 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 8 de diciembre de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada, Persona informante no revelada | 31 de agosto de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 4 de agosto de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada, Persona informante no revelada | 2 de agosto de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 2 de agosto de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 1 de agosto de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada | 29 de abril de 2005 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada, Persona informante no revelada | 23 de septiembre de 2004 | · | Presentación inicial | Inversión pasiva | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 51 insiders · 29 directivos · 17 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Joseph Talamo | SVP and CFO | 13 de enero de 2020 A | 59 644 | 0 | 0 | $0 |
| Robert S Vaters | President & CFO | 12 de agosto de 2015 P | 228 750 | 0 | 0 | $0 |
| Robert Dickey IV | Chief Financial Officer | 31 de diciembre de 2014 A | 12 066 | 0 | 0 | $0 |
| Larry Alan May | Chief Financial Officer | 2 de enero de 2013 A | 64 618 | 0 | 0 | $0 |
| David W. Slack | President & CBO | 9 de enero de 2023 A | 20 642 | 0 | 0 | $0 |
| Hans Keirstead | President of the Issuer's NeoStem Oncology, LLC subsidiary. | 9 de mayo de 2014 A | · | 0 | 0 | $0 |
| Ian Zhang | President and Managing Director, NeoStem (China), Inc. | 4 de abril de 2011 A | 10 000 | 0 | 0 | $0 |
| Mark Weinreb | President | 21 de mayo de 2009 A | 66 923 | 0 | 0 | $0 |
| Robert Joseph Aholt JR | Chief Operating Officer | 3 de octubre de 2005 A | 4 369 317 | 0 | 0 | $0 |
| Tariq Imam | SVP, Bus Dev, General Counsel | 9 de enero de 2026 A | 36 078 | 0 | 0 | $0 |
| James Nisco | SVP, Fin/Treas, Chief Actg Off | 9 de enero de 2026 A | 32 311 | 0 | 0 | $0 |
| Kristen K Buck | EVP, R&D and CMO | 9 de enero de 2026 A | 93 462 | 0 | 0 | $0 |
| Todd C Girolamo | CLO, SVP of Corp Dev | 14 de enero de 2022 F | 160 827 | 0 | 0 | $0 |
| Douglas W Losordo | Executive Vice President, Global Head of Research and Development and Chief Medical Officer | 13 de enero de 2020 A | 130 406 | 0 | 0 | $0 |
| Robin L Smith | Executive Chair of the Board | 2 de junio de 2015 A | 347 285 | 0 | 0 | $0 |
| Catherine M Vaczy | General Counsel | 13 de abril de 2015 A | 71 234 | 0 | 0 | $0 |
| Stephen W Potter | Executive Vice President | 31 de diciembre de 2014 A | 14 016 | 0 | 0 | $0 |
| Robert Dillman | Vice President, Oncology of the Issuer. The Reporting Person also serves as Chief Medical Officer of the Issuer's NeoStem Oncolo | 9 de mayo de 2014 A | · | 0 | 0 | $0 |
| Martin E Schmieg | Vice President - Corporate Dev | 25 de junio de 2012 A | · | 0 | 0 | $0 |
| Jonathan Sackner-Bernstein | VP Clinical Dev & Reg Affairs | 2 de abril de 2012 A | · | 0 | 0 | $0 |
| Jason Kolbert | VP of Strategic Business Development | 4 de enero de 2012 A | 8 000 | 0 | 0 | $0 |
| Mingsheng Shi | Chairman of the Board of Directors of Suzhou Erye Pharmaceutical Company Ltd., an entity 51%-owned by the Company. | 4 de enero de 2012 A | 3 650 770 | 0 | 0 | $0 |
| Alan G Harris | Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs | 4 de abril de 2011 A | · | 0 | 0 | $0 |
| Anthony Salerno | Vice President, Operations and Academic Affairs Exhibit List Exhibit 24 - Power of Attorney | 9 de junio de 2010 A | · | 0 | 0 | $0 |
| Jian M Zhang | Vice President, Pharmaceutical Operations, and General Manager of Suzhou Erye Pharmaceuticals Company Ltd., a 51% owned subsidi | 9 de junio de 2010 A | 3 650 770 | 0 | 0 | $0 |
| Christopher C Duignan | Vice President, Finance | 30 de noviembre de 2009 A | · | 0 | 0 | $0 |
| Lepore Teresa Linn Samuels | VP of Sales and Marketing | 29 de octubre de 2009 A | · | 0 | 0 | $0 |
| Renee Cohen | VP of Oper. & Corp. Strategy | 27 de febrero de 2008 A | 31 000 | 0 | 0 | $0 |
| Wayne A Marasco | Senior Scientific Advisor | 2 de junio de 2006 A | 1 436 713 | 0 | 0 | $0 |
| Cynthia Schwalm | Consejero | 9 de enero de 2026 A | 95 446 | 0 | 0 | $0 |
| Steven M Klosk | Consejero | 9 de enero de 2026 A | 95 815 | 0 | 0 | $0 |
| Anne Clem Whitaker | Consejero | 10 de enero de 2022 A | 182 635 | 0 | 0 | $0 |
| Michael H. Davidson | Consejero | 10 de enero de 2022 A | 209 753 | 0 | 0 | $0 |
| MYERS STEVEN S | Consejero | 10 de enero de 2022 A | 212 269 | 0 | 0 | $0 |
| Eric Wei | Consejero | 7 de febrero de 2017 S | 172 223 | 0 | 0 | $0 |
| Richard J Berman | Consejero | 9 de enero de 2017 A | 7 177 | 0 | 0 | $0 |
| Andrew L Pecora | Consejero | 22 de junio de 2016 A | 393 784 | 0 | 0 | $0 |
| Drew Bernstein | Consejero | 2 de junio de 2015 A | 10 000 | 0 | 0 | $0 |
| Martyn D Greenacre | Consejero | 2 de junio de 2015 A | 88 531 | 0 | 0 | $0 |
| Edward Geehr | Consejero | 29 de junio de 2012 A | · | 0 | 0 | $0 |
| Joseph Zuckerman | Consejero | 21 de mayo de 2009 A | 41 260 | 0 | 0 | $0 |
| RimAsia Capital Partners Manager, Ltd. | Propietario del 10% | 17 de septiembre de 2012 S | 105 306 | 0 | 0 | $0 |
| Fullbright Finance Ltd | Propietario del 10% | 28 de diciembre de 2009 P | 3 250 770 | 0 | 0 | $0 |
| Gregory B Brown | · | 9 de enero de 2026 A | 95 659 | 0 | 0 | $0 |
| David J Mazzo | · | 9 de enero de 2026 A | 311 890 | 0 | 0 | $0 |
| Mohammad Azab | · | 9 de enero de 2026 A | 104 925 | 0 | 0 | $0 |
| Heidi Henson | · | 9 de enero de 2026 A | 85 725 | 0 | 0 | $0 |
| Erkki Ruoslahti | · | 9 de enero de 2023 A | 20 000 | 0 | 0 | $0 |
| Peter G Traber | · | 10 de enero de 2022 A | 149 190 | 0 | 0 | $0 |
| Robert A Preti | · | 18 de mayo de 2017 F | 33 786 | 0 | 0 | $0 |
| Aholt Jr Family Trust | · | 5 de junio de 2006 S | 12 352 227 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 4 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 80 444 SH | 19 de agosto de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 191 371 SH | 19 de agosto de 2026 | Diario |
| DFSU · Dimensional ETF Trust | 0,00% | 100 NS | 31 de julio de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 8 NS | 31 de julio de 2026 | N-PORT |
LSTA Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 9 analistas
COMPRA
Objetivo mediano
$4.00
+172,1%
2 22,2%
Compra fuerte
4 44,4%
Compra
3 33,3%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
1 analistas · 2026-07-19Objetivo medio $4.00 +172,1%
Mín$4.00
Media$4.00
Máx$4.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 6, 2026